Date: 2017-08-01
Type of information: Clinical research agreement
Compound:
Company: Epizyme (USA - MA) US Oncology Research (USA - TX)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: clinical research
Action mechanism:
Disease: relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) with EZH2 mutations
Details:
- • On August 1, 2017, Epizyme and US Oncology Research , one of US largest networks of independent, community-based oncology practices dedicated to advancing high-quality treatments through clinical trials, announced a collaboration to screen and identify relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) patients with EZH2 mutations. Once identified, eligible candidates will be directed to Epizyme's ongoing Phase 2 clinical trial of tazemetostat as a single-agent treatment for relapsed or refractory patients with FL or DLBCL.
- Under the collaboration, US Oncology Research will implement a separate screening protocol in 68 locations in the U.S. to identify relapsed or refractory FL and DLBCL patients with tumors bearing EZH2 mutations who may be candidates for enrollment in Epizyme's ongoing Phase 2 clinical trial. US Oncology Research will direct identified patients to the tazemetostat Phase 2 clinical trial for protocol screening and potential enrollment into the trial. Sites began screening patients in July 2017 .mutations.
Financial terms:
Latest news:
Is general: Yes
